Search results
22 cze 2023 · The aim of our study was to analyze the influence of ethnic variations, tumor purity, and neoadjuvant chemotherapy (CT) on the determination of HRD scores as well as to evaluate feasibility of HRD testing with the Amoy HRD Focus Assay in routine clinical practice.
Key Takeaways. Prior to treatment initiation in advanced ovarian cancer, homologous recombination deficiency (HRD) testing is essential in determining the likely magnitude of benefit of poly...
8 paź 2024 · Homologous recombination deficiency (HRD) is recognized as a pan-cancer predictive biomarker that potentially indicates who could benefit from treatment with PARP inhibitors (PARPi). Despite its clinical significance, HRD testing is highly complex.
1 paź 2024 · We argue for the widespread adoption germline testing for all patients at the time of prostate cancer (PCa) diagnosis. Patients with metastatic hormone sensitive PCa (mHSPC) or mCRPC would ...
29 sty 2023 · Testing for a homologous recombination deficiency (HRD) in primary high-grade ovarian cancer is crucial for recommending the appropriate therapy. Patients with a BRCA germline mutation are defined as harboring an HRD deficiency.
22 lut 2017 · We will explore a proposed testing strategy using somatic tumor testing as an initial triage whereby those patients found with somatic testing to have HRD gene mutations are referred to genetics to determine if the mutation is germline.
17 lip 2024 · The main international guidelines strongly recommend the use of the homologous recombination deficiency (HRD) test in the selection of first-line maintenance therapy for patients with high-grade serous ovarian cancer.
